Species-dependent enantioselective pharmacokinetics of PNU-103017, a pyrone HIV protease inhibitor.

PNU-103017, 4-Cyano-N-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy- 2-oxo-2H-cycloocta(b) pyran-3-yl)methyl)phenyl)-benzenesulfonamide, is a selective HIV aspartyl protease inhibitor under evaluation as a potential oral treatment of Acquired Immunodeficiency Diseases. PNU-103017 is a racemic mixture of two enantiomers, designated PNU-103264 (R-) and PNU-103265 (S-). Stereoselective pharmacokinetics of the two enantiomers of PNU-103017 were observed in the dog, rat, and human after single and multiple dose administration of the racemate and were apparently species-dependent. Mean enantiomeric ratios of plasma concentrations (R-/S-) at each time point were greater than 1 in the dog, ranging from 1.22 to 3.06, but less than 1 in the rat and in the human, ranging from 0.44 to 0.80 and 0.23 to 0.73, respectively. A trend towards increased or decreased (farther from 1:1, R-/S-) enantiomeric ratio of plasma concentrations with time after each administration was also observed. The enantiomeric ratio remained unchanged after multiple dose administration in the rat, dog, and human although enzyme induction and increased plasma clearance were observed for both enantiomers.

[1]  M. Williams,et al.  Stereospecific determination of an HIV aspartyl protease inhibitor, PNU-103017, in rat, dog and human plasma using a Pirkle-concept high-performance liquid chromatographic column. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[2]  K. Koeplinger,et al.  Chromatographic measurement of drug-protein interaction: determination of HIV protease inhibitor-serum albumin association. , 1996, Analytical biochemistry.

[3]  K. Chiba,et al.  Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. , 1996, The Journal of pharmacology and experimental therapeutics.

[4]  W. Howe,et al.  Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. , 1995, Journal of medicinal chemistry.

[5]  J. Meinwald,et al.  Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[6]  Y. Yoshimura,et al.  Enantioselective pharmacokinetics in animals of pazinaclone, a new isoindoline anxiolytic, and its active metabolite , 1995, Biopharmaceutics & drug disposition.

[7]  F. Belpaire,et al.  Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin. , 1995, Chirality.

[8]  M. Nishikata,et al.  Effect of first-pass metabolism on enantioselective pharmacokinetics after oral administration of (+)-, (-)- and racemic homochlorcyclizine to rats. , 1994, Biological & pharmaceutical bulletin.

[9]  J. Gal,et al.  Stereoselective hydroxylation of tacrine in rats and humans. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[10]  M. Nishikata,et al.  Enantioselective Pharmacokinetics of Homochlorcyclizine: Disposition of (+)‐ and (–)‐Homochlorcyclizine after Intravenous and Oral Administration of Racemic Homochlorcyclizine to Rats , 1994, The Journal of pharmacy and pharmacology.

[11]  R. Kato,et al.  Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). , 1993, The Journal of pharmacology and experimental therapeutics.

[12]  K. Midha,et al.  Evidence that dogs do not model enantioselective pharmacokinetics of dl-methylphenidate in humans. , 1991, Journal of pharmaceutical sciences.

[13]  B. Moss,et al.  An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Jeffrey P. Jones,et al.  Stereochemical considerations in drug metabolism , 1987 .